
#AskDrDurie: What should we know about the FDA approval of ixazomib (Ninlaro®)?
In this week's video, Dr. Brian G.M. Durie discusses the recently FDA approved drug ixazomib (Ninlaro®).
Bottom Line:
Ninlaro is an important addition to the lineup of myeloma treatments.
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.
Previous Post
What should we know about FDA approval of daratumumab?
Next Post
Best of ASH 2015: What Patients and Caregivers Need to Know